REG - Genus - Capital Markets Event

GenusAnnouncement

01/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA9331Ra&default-theme=true

RNS Number : 9331R  Genus PLC  01 November 2023

 

For Immediate
Release

1 November 2023

 

Genus plc

("Genus", the "Group" or the "Company")

Capital Markets Event - Delivering the PRRS Resistant Pig ("PRP")

 

Genus plc (LSE:GNS), a leading global animal genetics company, is hosting a
Capital Markets Event ("CME") today at 10.00am in London for institutional
investors and sell-side analysts.

Chief Executive Officer, Jorgen Kokke, and Chief Financial Officer, Alison
Henriksen, will be joined by senior leaders from the Group's porcine division,
Pig Improvement Company ("PIC"), to take a deep dive into the Group's
pioneering PRRS* Resistant Pig ("PRP") programme and the path to
commercialisation.

PRRS is the most economically significant disease affecting US pork
production(1). Symptoms of PRRS include fever, respiratory distress, premature
births and increased post wean mortality. Genus has demonstrated that its PRP
is resistant to prevalent PRRS strains(2).

 

The Company is preparing for commercialisation of PRP whilst regulatory
approvals in various countries are in progress. The Colombian government was
the first to issue a positive determination for PRP last month, and, as
previously outlined, Genus anticipates approval from the United States Food
and Drug Administration ("FDA") in the first half of 2024.

 

Speakers at the event will outline:

·    The strength of PIC's platform; market-leading genetics, a
well-invested global supply chain to disseminate PRP genetics to customers,
deep relationships with long-term customers underpinned by the royalty model
and a world class team

·    The technical performance of PRP genetics; how the CD163 gene edit
works, why PIC's research shows it delivers PRRS resistance, the strong
intellectual property position and how PIC breeds homozygous edited animals

·    The impact PRRS has on the pork value chain; PRRS is an increasingly
endemic global disease affecting almost all major pork producing regions.
Research suggests that more than 60% of US sow herds are PRRS positive at any
given time(3) and that the average cost to US pig farmers is approximately
$6/pig

·    How PIC plans to disseminate PRP genetics; investments PIC has made
in the PRP supply chain ahead of commercialisation and how dissemination to
customer systems will work in practice once FDA and other regulatory approvals
have been granted

·    PIC's strategy for driving market acceptance; how PIC is developing
thoughtful and responsible messaging for all stakeholders in the pork value
chain, the research investments PIC is making to quantitatively demonstrate
the welfare and sustainability benefits, and the industry partners PIC is
working with to communicate the shared benefits of PRP

·    The PRP regulatory timeline; progress being made with the FDA and
regulatory bodies in other countries, including those that are important US
export markets

·    The opportunity for Genus; the global market opportunity, the
potential financial performance of PRP in the US and the prospect of
compelling returns on Genus's investments

A copy of the CME presentation will be made available on the Group's investor
relations website (https://www.genusplc.com/investors
(https://www.genusplc.com/investors) ) and a recording of the event will be
published as soon as practicable after the event.

 For further information please contact:

Genus plc            Tel: +44 (0)1256 345 970

Jorgen Kokke, Chief Executive Officer

Alison Henriksen, Chief Financial Officer

Anand Date, Investor Relations Director

Buchanan            Tel: +44 (0)207 466 5000

Charles Ryland; Chris Lane; Sophie Wills; Verity Parker

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

* Porcine Reproductive and Respiratory Syndrome virus

1 "Swine Disease Manual" (4(th) Edition), Edited by EJ Neumann, A Ramirez, and
KJ Schwartz, Iowa State University, College of Veterinary Medicine;
https://vetmed.iastate.edu/vdpam/about/production-animal-medicine/swine/swine-disease-manual
(https://vetmed.iastate.edu/vdpam/about/production-animal-medicine/swine/swine-disease-manual)

2 Studies of the safety and efficacy of Genus's PRP are being reviewed by the
US Food and Drug Administration and other regulatory agencies around the world

3 University of Minnesota, Morrison Swine Health Monitoring Program

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRBDGSXXDGXB